Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses by Satterfield, Brent C et al.
SHORT REPORT Open Access
Serologic and PCR testing of persons with
chronic fatigue syndrome in the United States
shows no association with xenotropic or
polytropic murine leukemia virus-related viruses
Brent C Satterfield
1*, Rebecca A Garcia
1, Hongwei Jia
2, Shaohua Tang
2, HaoQiang Zheng
2, William M Switzer
2
Abstract
In 2009, a newly discovered human retrovirus, xenotropic murine leukemia virus (MuLV)-related virus (XMRV), was
reported by Lombardi et al. in 67% of persons from the US with chronic fatigue syndrome (CFS) by PCR detection
of gag sequences. Although six subsequent studies have been negative for XMRV, CFS was defined more broadly
using only the CDC or Oxford criteria and samples from the US were limited in geographic diversity, both
potentially reducing the chances of identifying XMRV positive CFS cases. A seventh study recently found polytropic
MuLV sequences, but not XMRV, in a high proportion of persons with CFS. Here we tested blood specimens from
45 CFS cases and 42 persons without CFS from over 20 states in the United States for both XMRV and MuLV. The
CFS patients all had a minimum of 6 months of post-exertional malaise and a high degree of disability, the same
key symptoms described in the Lombardi et al. study. Using highly sensitive and generic DNA and RNA PCR tests,
and a new Western blot assay employing purified whole XMRV as antigen, we found no evidence of XMRV or
MuLV in all 45 CFS cases and in the 42 persons without CFS. Our findings, together with previous negative reports,
do not suggest an association of XMRV or MuLV in the majority of CFS cases.
Findings
T h ex e n o t r o p i cm u r i n el e u k e mia virus (MuLV)-related
virus (XMRV) is a retrovirus capable of infecting human
cell lines and was recently found in some persons with
prostate cancer [1]. Conflicting reports of XMRV in Eur-
o p ea n dt h eU Ss h o wX M R Vp r e v a l e n c eb e t w e e n0a n d
27% in prostate cancer patients [2-4]. More recently,
Lombardi et al. reported finding XMRV in 67% of per-
sons with chronic fatigue syndrome (CFS) and in 3.6% of
healthy controls using PCR, serology, and virus isolation
[5]. However, six subsequent studies found no association
of XMRV and CFS in the US, Europe and China [6-11].
A more recent study failed to detect XMRV, but found a
polytropic MuLV most similar to mouse endogenous ret-
roviruses in 87% of CFS cases [12].
These discrepant results may be explained by differ-
ences in assay sensitivities used in each study, genetic
heterogeneity of XMRV, geographic distribution of the
virus, or by differences in subgroups of people with
CFS. Since PCR assays have become standard tools in
research and clinical laboratories, and each study
reported using very sensitive assays, it is very unlikely
that subtle assay differences contribute to these discor-
dant test results. Some studies also used the same PCR
assays as the initial study or generic tests for detecting
both XMRV and other variants of MuLV [6-9], support-
ing further that the negative results were not due to
assay differences or the ability to detect divergent viral
strains.
The 1994 International Research Case Definition of
CFS, currently used by most investigators, acknowledges
that CFS subtypes are likely to occur, and encourages
investigators to examine criteria to stratify cases, such as
by type of onset, gradual or acute [11]. Variations in the
approach to case ascertainment as well as in the severity
of illness and type of onset could result in different
spectrum of illness and potential differences in
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possible that the European studies [6-8] did not find
XMRV due to regional differences or that the previous
CDC study [9] was too localized to the regions around
Georgia and in Wichita, Kansas. Similarly, a possible
geographic clustering of XMRV infection has been
observed in prostate cancer patients with most cases
occurring in the US [2-4].
We tested fresh, EDTA-treated blood specimens from
30 CFS cases from 17 states in the US who consented
to participate in a research study and who were
recruited via an online announcement (Table 1). Blood
was also collected from one additional person with CFS
using heparin-containing collection tubes. Of these 31
persons, 26 were diagnosed by a doctor and 5 were self
diagnosed. All CFS patients met the 1994 research case
definition and specified a minimum of 6 months of
post-exertional malaise and a high degree of disability,
more closely resembling persons with CFS in the Lom-
bardi et al. report than those CFS cases in previous stu-
dies. Specifically, we used Dr. Bell’s CFS severity scale as
an indicator of the degree of disability [13]. The mean
low score experienced by our participants with “severe
CFS” was 22.3, which is defined as “Moderate to severe
symptoms at rest. Severe symptoms with any exercise;
overall activity level reduced to 30%-50% of expected.
Unable to leave house except rarely; confined to bed
most of day; unable to concentrate for more than
1h o u rad a y ” [13]. We also tested another 14 self-
diagnosed CFS samples from persons having a severity
score above 50 or having an unreported CFS severity
(unclassified CFS) and 42 persons that did not have
CFS. In total, samples came from more than 20 states,
providing a broader geographic distribution than pre-
vious studies from the US (Table 1).
Blood samples were shipped from collection centers
overnight. Most were processed immediately upon arri-
val, but a few samples were incubated in the refrigerator
for 1 to 2 days prior to separation of the blood compo-
nents. For component separation, blood was centrifuged
and the buffy coat, including the peripheral blood
mononuclear cells (PBMCs), was immediately and care-
fully removed. The buffy coat was either processed
immediately or stored at -20°C for later analysis. Nucleic
acids were extracted using the Qiagen blood DNA mini-
kit protocol (Qiagen, Valencia, CA). Extracted DNA was
quantitated using the Nanodrop spectrophotometer
(Thermo Scientific, Wilmington, DE) and checked for
integrity with a minimum 260/280 ratio of 1.8 and by ß-
actin PCR. Plasma was immediately frozen for later
analysis.
PCR analysis was performed on PBMC DNA using
three previously described tests (Table 2), two for the
polymerase (pol) gene, and one for the gag gene used in
Urisman et al.,L o m b a r d iet al., and Lo et al. [1,5,9,14].
The pol real-time PCR test was used to analyze DNA
samples from all study participants. At the CDC, nested
gag (external primers GagOF and GagOR; internal pri-
mers GagIF and GagIR) and pol (external primers XPO-
LOF an XPOLOR; internal primers XPOLIF and
X P O L I R )P C Rw a su s e dt ot e s tas u b s e to fs p e c i m e n s
for which sufficient DNA remained, including 28 sam-
ples from “severe CFS” persons, 11 “unclassified CFS”
and 9 controls [1,9]. 2.5 μgo fD N A( 8 3 3n go fP B M C
DNA) was used in the pol real-time PCR test, providing
for 3.3 to 8.3 times the PBMC DNA used by Lombardi
et al. [5,14]. Dilutions of DNA from XMRV-infected
22Rv1 human prostate carcinoma cells were used as
positive controls in this test [15]. 1.0 μgo fD N A( 3 3 3
ng of PBMC DNA) was used in the nested pol and gag
PCR tests at the CDC for which 1,000 and 10 copies of
the XMRV(VP62) plasmid were used as positive controls
[1,9]. A subset of 48 plasma samples were tested for
viral RNA sequences by RT-PCR using primers from
the nested gag assay and also by using a new quantita-
tive RT-PCR test that generically detects MuLV and
XMRV gag sequences. Both RT-PCR tests could detect
between 10 - 25 copies of XMRV (VP62) RNA. Since
antibody responses are hallmarks of retroviral infection,
we also used a newly modified Western blot (WB) test
to detect anti-XMRV antibodies in plasma [1,9]. Serolo-
gic tests could potentially also identify low-level or
latent XMRV infection not otherwise detectable by PCR.
Briefly, XMRV-infected DU145 prostate cells (C7) were
grown in complete HuMEC serum free medium supple-
mented with 1% HuMEC and 50 ug/ml bovine pituitary
Table 1 Statistics on CFS patients and controls from the U.S
Race Gender
Population N States AvgAge Avg Duration of Illness Caucasian Other Female Male
Severe CFS 31 17 44 12.8 yrs 87% 13% 61% 39%
Unclassified CFS 14 9 40 12.3 yrs 79% 21% 86% 14%
CFS Negative 42 12 23 n/a 71% 29% 45% 55%
TOTAL 87 21 78% 22% 57% 43%
Shows the number of states within the U.S. that participants were recruited from, the average participant age, the average time since the onset of CFS
symptoms, the race and gender of participants from each class of sample.
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Page 2 of 7extract (Invitrogen). Tissue culture supernatants were
clarified by centrifugation and by passage through a
0.45 um filter. XMRV was purified from 150 ml C7
supernatant using the ViraTrap Retrovirus Maxiprep Kit
(Bioland Scientific LLC) following the manufacturer’s
protocol. 150 ul of purified XMRV was denatured with
SDS-PAGE sample buffer at 95°C for 10 minutes, and
viral proteins were separated by gel electrophoresis in a
NuPAGE 4-12% Bis-Tris gel (Invitrogen) for WB testing
as previously described but modified by using horserad-
ish peroxidase conjugated protein G instead of protein
A/G [9]. Seroreactivity was defined by reactivity to viral
Env and/or Gag proteins of the expected size as seen in
the positive control antisera (Figure 1). This new WB
test accurately detects XMRV antibodies in three experi-
mentally infected macaques equivalent to detection
using recombinant proteins in recently described immu-
noassays (Figure 1b) [16]. All PCR and WB testing at
the CDC were performed blinded to diagnosis.
Using this comprehensive testing strategy to test CFS
samples from persons with post-exertional malaise from
a variety of US states, we did not find any serologic or
molecular evidence of XMRV or MuLV in persons with
or without CFS (Table 3, Figures 1, 2 and 3). These
results suggest that neither the limited geographic local-
ity of previous publications nor the post-exertional
malaise criteria explain the discrepant results seen in
previous studies.
For detection of any new virus, false positive and
negative results are always a concern, especially when
b o n af i d ep o s i t i v ea n dn e g a t i v ec l i n i c a ls p e c i m e n sa r e
not available for assay validation. The PCR tests in this
study have been previously shown to detect low levels
(≤ 10 copies) of XMRV plasmid in high genomic DNA
backgrounds and are capable of generically detecting
XMRV and diverse MuLVs [5,9,14]. While all the PCR
tests used in XMRV studies reported similar sensitiv-
ities, it is important to note that each used a different
Table 2 PCR oligos and conditions
Oligo Name Sequence (5’®3’) Location
1 Sample Conditions
pol Forward GGGGATCAAGCCCCACATA 2794 to
3062
2.5 μg DNA 95°C for 20 s followed by 45 cycles of 95°C for 1 s and 60°C for
20 s [14]
Reverse GGTGGAGTCTCAGGCAGAAAA
Probe [6FAM] TGTTCCAGGGGGACT
GGCAAGGTACCAccctgg [DABC]
2,3
pol2
XPOLOF
CCGTGCCCAACCCTTACAACCTCT 2961 to
3330
1.0 μg DNA 40 cycles of 94°C for 30 s, 50°C for 30 s, 72°C for 45 s for both
primary and nested PCR [9]
XPOLOR CCGAGGTTCCCTAGGGTTTGTAAT
XPOLIF TCCACCCCACCAGTCAGCCTCTCT
XPOLIR AAGTGGCGGCCAGCAGTAAGTCAT
XPOLP TTGATGAGGCACTGCACAGAGACC Probe
gag1 GagOF ATCAGTTAACCTACCCGAGTCGGAC 419 to
1149
0.25 μg DNA;
RNA from 62 μL
plasma
40 cycles of 94°C for 30 s, 50°C for 30 s, 72°C for 45 s for both
primary and nested DNA PCR [5,9]. RT-PCR; Primer 1154R was
used for cDNA synthesis at 42°C for 1 hr with the IScript Select
cDNA kit (BioRad) followed by 85°C, 5 min to stop the reaction.
Nested PCR was then performed as for DNA testing using the
Expand High Fidelity PCR System (Roche) and AmpliTaq (Applied
Biosystems) for the primary and nested PCRs.
GagOR GCCGCCTCTTCTTCATTGTTCTC
GagIF GGGGACGAGAGACAGAGACA
GagOR CAGAGGAGGAAGGTTGTGCT
XGagP2 ACCTTGCAGCACTGGGGAGATGTC Probe
gag2
Forward
AGGTAGGAACCACCTAGTYC 1581 to
1764
RNA from 62 μL
plasma
RT-PCR using AgPath-ID one step RT-PCR kit (Applied
Biosystems) and BioRad iQ5 iCycler. Reverse primer used for
cDNA synthesis at 45°C for 20 min; 95°C for 10 min. 55 cycles at
95°C, 30 s, 52°C, 30 s, 62°C, 30 s.
Reverse GTCCTCAGGGTCATAAGGAG
Probe F [6FAM]
AGCGGGTCTCCAAAACGCGGGC
[BHQ1]
3
1620
Probe R [6FAM]
CCTTTTACCTTGGCCAAATTGGTGGGG
[BHQ1]
3
1673
1Reference sequence was the VP62 XMRV strain (GenBank: EF185282.1).
2Lower case bases were added to form the stem.
3[6FAM] and [DABC] and [BHQ1] are the fluorophore FAM and the quenchers Dabcyl and Blackhole, respectively.
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Figure 1 Absence of antibodies to XMRV in plasma from persons with and without CFS from the US.a .A n t i b o d yt i t e r so fp o s i t i v e
control anti-sera to purified XMRV antigen in WB testing. Specific antisera tested are provided at the top of each WB. Arrows indicate observed
titers for each antiserum. Locations of reactivity to specific viral proteins are indicated. Env (gp69/71), envelope; TM (p15E), transmembrane; MA
(p15), matrix; Gag (pr68); CA (p30), capsid. Molecular weight markers (kD) are provided on the right of the WB. Sizes of expected viral proteins
are provided to the left of the WB. b. Detection of XMRV antibodies in three experimentally-infected macaques (RII, RYh and RLq). Days post
infection and immunization with XMRV are shown with arrows [16]. Locations of reactivity to specific viral proteins are indicated. Env (gp69/71),
envelope; TM (p15E), transmembrane; MA (p15), matrix; Gag (pr68); CA (p30), capsid. Molecular weight markers (kD) are provided on the right of
the WB. Sizes of expected viral proteins are provided to the left of the WB. c. Representative WB results for CFS cases and persons without CFS.
Lane 1, 1:250 dilution of anti-Friend MuLV whole virus, goat polyclonal antisera; lane 2, XMRV negative blood donor plasma; lanes 3, 4, 9, 11 are
plasma from persons without CFS; lanes 5 - 8, 10, 12, 14 - 17, 19, 20, 23 - 27 are plasma from persons with severe CFS; lanes 13, 18, 21, and 22
are plasma from persons with unclassified CFS. Locations of reactivity to specific viral proteins are indicated; Env (gp69/71), envelope; TM (p15E),
transmembrane; MA (p15), matrix; Gag (pr68); CA (p30), capsid. Molecular weight markers (kD) are provided on the left of the WB.
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Page 4 of 7amount of starting DNA. Specifically, the assays of Lo
et al. and Lombardi et al. can at best detect 1 copy of
XMRV/MuLV in a background of 30 to 50 ng and 100
to 250 ng of DNA respectively [5,12]. However, in our
study, we use the most sensitive PCR test reported to
d a t e ,w i t had e t e c t i o nl i m i to f1c o p yo fX M R Vo r
MuLV in 2,500 ng of DNA, a 10-83X improved detec-
tion limit over the assays used by Lombardi et al. and
Lo et al. This indicates that any one of the assays would
be able to detect XMRV or MuLV if present in the sam-
ples. Moreover, a recent study also demonstrated the
importance of using at least 600 ng of input DNA to
increase detection of XMRV in prostate cancer patients
[17]. XMRV could also be present in blood at levels
below the detection limit of PCR, but this seems unli-
kely given the relatively high frequency of infection
reported by Lombardi et al. and Lo et al. in people with
CFS using tests with less sensitive PCR tests [5,12].
Unlike other reports [5,12], we also found no evidence
of active XMRV/MuLV viremia using highly sensitive
RT-PCR tests excluding possibilities of peripheral infec-
tion seeding the blood compartment from other body
locations. Furthermore, WB testing did not detect
XMRV or MuLV antibodies in the plasma samples,
arguing against the development of an XMRV/MuLV-
specific humoral immune response, as is commonly
seen with other human retroviral infections, and
Table 3 Absence of XMRV in CFS patients from the U.S
XMRV Positive
Population N pol pol2 gag1 WB gag1
RT-PCR
gag2
RT-PCR
Severe CFS 31 0/31 0/28 0/28 0/28 0/28 0/28
Unclassified CFS 14 0/14 0/11 0/11 0/11 0/11 0/11
CFS Negative 42 0/42 0/9 0/9 0/9 0/9 0/9
TOTAL 87 0/87 0/48 0/48 0/48 0/48 0/48
Cooperative Diagnostics pol real-time PCR test, CDC pol (pol2) and gag DNA
PCR, gag RT-PCR, and Western blot (WB) results.
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Figure 2 Absence of XMRV/MuLV sequences by PCR of PBMC
DNA of persons with and without CFS from the US.
Representative nested polymerase (pol2) PCR results. Lanes 1 and 2
are results from persons without CFS; lanes 3 - 8, 10 and 11 are
results from patients classified with severe CFS; lanes 9, and 12 - 14
are results from patients with unclassified CFS; lane 15, negative
human PBMC DNA control; lanes 16 and 17, water only controls;
lanes 18 and 19, assay sensitivity controls consisting of 10
1 and 10
3
copies of XMRV VP62 plasmid DNA diluted in a background of 1 μg
of human PBMC DNA, respectively.
pol
Figure 3 Absence of XMRV/MuLV sequences by real-time PCR
in PBMC DNA of persons with and without CFS from the US.
Representative real-time XMRV polymerase (pol) PCR results. Upper
panel; pol amplification plot using XMRV synthetic DNA diluted in a
background of 2.5 ug of DNA from whole blood to 12,000, 1,200,
120 and 12 copies and negative (water and DNA) controls
demonstrating the sensitivity and dynamic linear range of the assay.
Lower panel; pol amplification plot for DNA from 40 persons,
including 18 with severe CFS, 8 with unclassified CFS, and 14
without CFS. Two positive controls (DNA from 17 XMRV infected
22Rv1 cells spiked into 2.5 μg of human leukocyte DNA) for the pol
PCR, and two negative controls (2.5 μg of DNA) are also shown.
Only the two positive controls were detected in this testing.
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Page 5 of 7precluding the possibility of low level viral infection in
blood or in other reservoirs. Given the recent finding
that an XMRV antibody test, using even a single XMRV
protein, had 100% sensitivity for XMRV detection in
monkeys after the second week of infection with
XMRV, it is highly unlikely that our WB test, which
uses purified, whole XMRV as antigen and detects
XMRV antibodies in infected macaques, would have
missed detecting XMRV infection [16].
It is also important to note that the report by Lo et al.
is not a confirmation of the Lombardi et al. study since
like previous studies, this study also failed to identify
XMRV in any of the CFS samples or controls [6-12].
Rather, Lo et al. identified a polytropic MuLV sequence
in a majority of CFS samples that most closely resembles
nonfunctional viruses in mouse genomic DNA, which
was confirmed by a truncated Gag sequence in one CFS
specimen in their study. Thus, without viral isolation or
complete genomes, the infectivity and person-to-person
transmissibility of these polytropic viruses are unclear.
Others have described the lengthy history and ubiquitous
nature of mouse cell or DNA contamination, even in
laboratories that have never worked with MuLV’s, and
concluded that contamination cannot be excluded as a
source of the MuLV-like sequences in some studies [18].
Since this report, four laboratories have reported that
100% of polytropic MuLV and/or XMRV sequences
found in their CFS and prostate cancer samples stemmed
from contamination from commercial reagents and/or
other sources [11,19-21]. In addition, a review on XMRV
describes the potential dangers from using polymerases
with antibody mediated hot starts, especially those devel-
oped from mouse hybridoma cells, such as the Platinum
Taq used by Lo et al. [22]. While Lo et al. did not find
mouse cell contamination by a retrospective screen of
their samples for murine mitochondrial sequences or
through the use of numerous water controls, mtDNA
screening and water controls are not sufficient to detect
the majority of murine genomic DNA contamination
[19,20]. Hue et al. showed that 100% of published XMRV
sequences from CFS and prostate cancer samples have
less sequence variation than occurs within XMRV in the
22Rv1 cell line, concluding that any discovery of these
conserved XMRV sequences in patient samples was due
to contamination [23]. Given the high degree of known
risk for contamination even in laboratories that
have never worked with MuLV’s and the historical con-
tamination of human cell lines with MuLVs and other
retroviruses [18,24], it is imperative that murine contami-
nation controls be run in parallel with all human testing.
Since both polytropic and xenotropic MuLV’s are capable
of infecting non-murine cells, other controls will need to
be developed to rule out contamination from non-murine
sources.
I nc o n c l u s i o n ,w eh a v eu s e dac o m p r e h e n s i v et e s t i n g
strategy, including highly sensitive PCR tests and a novel
XMRV WB assay, to show that neither the limited geo-
graphic differences of previous studies within the United
States nor the condition of post-exertional malaise are the
reason for the discordant study results. Further, with what
are now seven negative studies, it is highly unlikely that
XMRV is present in people with CFS or in control popula-
tions as frequently as has been previously reported. The
amount of specimen from each of the positive studies has
been limiting for independent confirmation of the test
results. Thus, different study designs are needed to further
investigate an association of XMRV and MuLV in persons
with CFS, including carefully defined case control studies
in which specimens are collected and processed the same,
followed by coded and blinded testing at independent
laboratories reporting both detection and absence of infec-
tion with these viruses.
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